• FDA approval for Myqorzo marks a significant milestone for Cytokinetics, addressing a substantial medical need in symptomatic obstructive hypertrophic cardiomyopathy.
• Truist Financial sets a price target of $84 for CYTK, indicating a potential upside of approximately 24.76% from its trading price on December 22, 2025.
• The stock has shown volatility with a 52-week trading range between $29.31 and $70.98, reflecting the market's response to the company's developments.

Cytokinetics Incorporated (NASDAQ: CYTK) is a biopharmaceutical company focused on developing muscle biology-driven treatments. The company recently received FDA approval for Myqorzo (aficamten), a drug targeting symptomatic obstructive hypertrophic cardiomyopathy (oHCM). This approval is a significant milestone, as Myqorzo aims to improve patients' functional capacity and alleviate symptoms.

On December 22, 2025, Srikripa Devarakonda from Truist Financial set a price target of $84 for CYTK. At that time, the stock was trading at $67.33, suggesting a potential upside of approximately 24.76%. The stock has since increased to $67.57, reflecting a 7.73% rise or $4.85, with a trading range today between $63.18 and $70.98.

The FDA approval of Myqorzo is crucial for Cytokinetics, as it addresses a significant medical need. The drug functions as an allosteric and reversible inhibitor of cardiac myosin motor activity, reducing cardiac contractility and left ventricular outflow tract obstruction. However, it carries a Boxed WARNING due to the risk of heart failure, necessitating regular echocardiogram assessments for patients.

CYTK's market capitalization stands at approximately $8.04 billion, with a trading volume of 5,494,603 shares on the NASDAQ exchange today. The stock's highest price over the past year is $70.98, while the lowest was $29.31. This volatility reflects the market's response to the company's recent developments and future potential.